Alzheimer's Disease Pathogenesis

Alzheimer's Disease Pathogenesis

Overview

Alzheimer's Disease Pathogenesis represents the complex series of molecular and cellular events that lead to neurodegeneration in Alzheimer's disease (AD). This page provides a comprehensive mechanistic model integrating amyloid biology, tau pathology, neuroinflammation, synaptic dysfunction, metabolic disturbances, and genetic risk factors into a unified framework for understanding disease progression and identifying therapeutic targets. [@hardy2002]

Introduction

Alzheimer's disease is the most common cause of dementia, affecting over 55 million people worldwide. The pathogenesis of AD involves multiple interconnected mechanisms that work together to cause progressive neurodegeneration, beginning decades before clinical symptoms appear. The amyloid cascade hypothesis remains the dominant framework, but contemporary models recognize the complexity of bidirectional relationships between amyloid, tau, neuroinflammation, and synaptic loss. [@selkoe2016]

Key Statistics

• Prevalence: 6.5 million Americans aged 65+ (2023)
• Disease duration: Typically 10-20 years from pathology onset to symptoms
• Brain weight loss: Up to 20% reduction in advanced cases
• Economic burden: $345 billion annually in the US (2023)

Core Pathological Features

Amyloid-Beta (Aβ)

...

Alzheimer's Disease Pathogenesis

Overview

Alzheimer's Disease Pathogenesis represents the complex series of molecular and cellular events that lead to neurodegeneration in Alzheimer's disease (AD). This page provides a comprehensive mechanistic model integrating amyloid biology, tau pathology, neuroinflammation, synaptic dysfunction, metabolic disturbances, and genetic risk factors into a unified framework for understanding disease progression and identifying therapeutic targets. [@hardy2002]

Introduction

Alzheimer's disease is the most common cause of dementia, affecting over 55 million people worldwide. The pathogenesis of AD involves multiple interconnected mechanisms that work together to cause progressive neurodegeneration, beginning decades before clinical symptoms appear. The amyloid cascade hypothesis remains the dominant framework, but contemporary models recognize the complexity of bidirectional relationships between amyloid, tau, neuroinflammation, and synaptic loss. [@selkoe2016]

Key Statistics

• Prevalence: 6.5 million Americans aged 65+ (2023)
• Disease duration: Typically 10-20 years from pathology onset to symptoms
• Brain weight loss: Up to 20% reduction in advanced cases
• Economic burden: $345 billion annually in the US (2023)

Core Pathological Features

Amyloid-Beta (Aβ)

Amyloid-beta peptides are produced through proteolytic cleavage of the [Amyloid Precursor Protein](/entities/app-protein) (APP), a type I transmembrane protein of unknown physiological function. APP can be processed through two major pathways: [@heneka2015]

Amyloidogenic Processing (Aβ Production)

Non-amyloidogenic pathway: [@de2016]
APP → α-secretase → sAPPα → carboxyterminal fragment (CTF) → γ-secretase → p3 peptide

Amyloidogenic pathway (Aβ production): [@wang2019]
APP → BACE → sAPPβ → CTF99 → γ-secretase → Aβ peptides (Aβ40, Aβ42)

BACE1 (β-secretase) performs the rate-limiting step in amyloid production, cleaving APP at the N-terminus of the Aβ sequence. γ-secretase (a complex of PSEN1, PSEN2, NCT, APH-1, PEN-2) performs the final cleavage, generating Aβ peptides of varying lengths. Aβ42 is more aggregation-prone than Aβ40 and is the primary species found in plaques. [@serranopozo2011]

Aβ Aggregation Pathway

Aβ peptides undergo a conformational transition from random coil to β-sheet structure, leading to: [@querfurth2010]

Oligomerization: Soluble Aβ oligomers (synaptotoxic)

Protofibril formation: Intermediate aggregation species

Fibril elongation: Mature amyloid fibrils

Plaque deposition: Dense core plaques, diffuse plaques

Aβ Toxicity Mechanisms

• Synaptic dysfunction: Aβ oligomers bind to prion protein (PrP^C) and disrupt synaptic signaling
• Oxidative stress: Metal-catalyzed ROS generation
• Calcium dysregulation: Membrane pore formation, receptor dysregulation
• Mitochondrial dysfunction: Complex IV inhibition, ATP depletion
• Inflammation activation: NLRP3 inflammasome activation in microglia

Tau Pathology

Tau is a microtubule-associated protein that stabilizes neuronal axons. In AD, tau becomes abnormally hyperphosphorylated, leading to loss of function and gain of toxic properties. [@calsolaro2016]

Tau Hyperphosphorylation Sites

Over 40 serine/threonine phosphorylation sites have been identified on tau in AD brain. Key sites include: [@hampel2021]

• Ser202/Thr205 (AT8 epitope) - early marker
• Ser396/Ser404 (PHF1 epitope) - disease progression marker
• Thr181 - biomarker candidate

Tau Kinases

Multiple kinases contribute to tau hyperphosphorylation: [@scheltens2016]

• GSK-3β: Primary kinase, tau kinase activity increased in AD
• CDK5: Activated by p25/p35, hyperphosphorylates tau
• MAPK family: ERK1/2, JNK, p38
• CK2 (Casein Kinase 2): Phosphorylates multiple sites

Tau Phosphatases

PP2A (Protein Phosphatase 2A) accounts for ~70% of tau phosphatase activity in brain. PP2A activity is reduced in AD through:

• Methylation defects (PME)
• Inhibitory phosphorylation (Tyr307)
• Endogenous inhibitors (I1PP2A, I2PP2A)

Neurofibrillary Tangle (NFT) Formation

Hyperphosphorylated tau dissociates from microtubules, leading to:

Microtubule destabilization and transport defects

Tau oligomerization in cytosol

Paired helical filament (PHF) formation

Neurofibrillary tangle accumulation

Neuronal death and Braak staging progression

Neuroinflammation

Chronic neuroinflammation is a hallmark of AD, with microglial and astrocyte activation observed throughout disease progression.

Microglial Activation States

• Homeostatic microglia: Survey brain parenchyma, ramified morphology
• Disease-associated microglia (DAM): Triggered by Aβ and tau, clustered around plaques
• Neurodegenerative microglia (NG): Found in regions of neuronal loss

Inflammatory Mediators in AD

| Mediator | Source | Effect |
|----------|--------|--------|
| IL-1β | Microglia | Promotes tau pathology, synaptic dysfunction |
| TNF-α | Microglia/Astrocytes | Synaptic pruning, neuronal death |
| IL-6 | Astrocytes | Acute phase response, inhibits neurogenesis |
| IL-18 | Microglia | IFN-γ dependent, promotes inflammation |
| TGF-β | Various | Modulates microglial phenotype |

Complement System

• C1q: Initiates classical complement, tags synapses for elimination
• C3/C3R: Critical for microglial phagocytosis
• C5a: Pro-inflammatory anaphylatoxin

Synaptic Dysfunction

Synaptic loss is the strongest correlate of cognitive impairment in AD, occurring before neuron loss.

Presynaptic Changes

• Synaptic vesicle depletion: Reduced readily-releasable pool
• Release probability changes: Impaired short-term plasticity
• Calcium handling defects: Reduced synaptotagmin-1 function

Postsynaptic Changes

• AMPA receptor trafficking: Reduced surface expression
• NMDA receptor dysregulation: Altered subunit composition
• mGluR5 hyperactivity: Calcium dysregulation
• GABAergic dysfunction: Inhibitory/excitatory imbalance

Structural Changes

• Spine density reduction: 25-45% loss in AD hippocampus
• Spine morphology changes: Loss of mushroom spines
• Synaptic size reduction: Smaller active zones

Metabolic Dysfunction

AD is increasingly recognized as a metabolic disorder affecting brain glucose metabolism.

Cerebral Glucose Hypometabolism

• Reduced FDG-PET signal: 20-40% in posterior cingulate
• Cause: Mitochondrial dysfunction, insulin resistance
• Consequence: ATP deficits, impaired neurotransmission

Insulin Resistance

Brain insulin resistance involves:

• IRS-1 serine phosphorylation: Inhibitory phosphorylation at Ser636
• PI3K/Akt signaling defects: Reduced downstream signaling
• Akt activity reduction: Impaired tau phosphorylation control

Mitochondrial Dysfunction

• Complex IV inhibition: By Aβ and oxidative stress
• mtDNA mutations: Accumulation with age
• Dynamics defects: Impaired fission/fusion
• Mitophagy impairment: Reduced clearance of damaged mitochondria

Molecular Mechanisms

Integrated Amyloid-Tau Model

The relationship between amyloid and tau is bidirectional:

Neuroinflammation Cascade

Genetic Risk Factors

Autosomal Dominant AD Genes

| Gene | Chromosome | Function | Mutations |
|------|------------|----------|-----------|
| APP | 21q21 | Amyloid precursor protein | 40+ pathogenic mutations |
| [PSEN1](/entities/psen1) | 14q24.3 | [γ-secretase](/entities/gamma-secretase) component | 200+ mutations |
| [PSEN2](/entities/psen2) | 1q42.13 | γ-secretase component | 40+ mutations |

APOE Polymorphism

[APOE](/proteins/apoe) (apolipoprotein E) is the major genetic risk factor for sporadic AD:

| Allele | Frequency | AD Risk | Mechanism |
|--------|-----------|---------|-----------|
| ε3 | 77% | Baseline | Normal function |
| ε4 | 14% | 3-4x increased | Reduced [Aβ](/proteins/amyloid-beta) clearance, impaired repair |
| ε2 | 8% | Reduced | Enhanced clearance |

APOE4 effects:

• Reduced Aβ clearance across [BBB](/entities/blood-brain-barrier)
• Enhanced Aβ aggregation
• Impaired synaptic plasticity
• Increased tau pathology
• Microglial phenotype shifts

TREM2 Variants

[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) variants increase AD risk ~3-fold:

• R47H: Reduces ligand binding
• R62H: Impaired signaling
• TREM2 KO: Reduced microglial clustering around plaques

Therapeutic Approaches

Disease-Modifying Therapies

Anti-Amyloid Immunotherapy

• [Lecanemab](/entities/lecanemab) (Leqembi): Clears Aβ plaques, FDA approved 2023
• [Donanemab](/entities/donanemab): Phase 3 positive, removes amyloid and slows progression
• Aduhelm (withdrawn): First anti-Aβ antibody

Anti-Tau Approaches

• Antisense oligonucleotides: Reduce tau expression
• Kinase inhibitors: [GSK-3β](/entities/gsk3-beta), [CDK5](/genes/cdk5) modulators
• [Tau](/proteins/tau) aggregation inhibitors: Methylene blue derivatives

Neuroinflammation Modulation

• TREM2 agonists: Enhance microglial function
• CSF1R antagonists: Reduce microglial proliferation
• [NLRP3](/entities/nlrp3-inflammasome) inhibitors: Block inflammasome activation

Symptomatic Treatments

| Target | Drug Class | Examples |
|--------|-----------|----------|
| Cholinergic | AChE inhibitors | [Donepezil](/entities/donepezil), [Rivastigmine](/entities/rivastigmine), Galantamine |
| Glutamatergic | NMDA antagonist | Memantine |
| Neuropsychiatric | Various | Antidepressants, antipsychotics |

Biomarkers

Fluid Biomarkers

• Aβ42/40 ratio: Reduced in CSF (plasma now available)
• Total tau: Elevated in CSF
• Phospho-tau (Thr181): Elevated in CSF/plasma
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) (NfL): Axonal damage marker

Imaging Biomarkers

• Amyloid PET: Florbetapir, Florbetaben
• Tau PET: Flortaucipir
• FDG-PET: Hypometabolism patterns
• MRI: Atrophy patterns

Conclusion

Alzheimer's disease pathogenesis involves a complex interplay of amyloid accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and metabolic disturbances. While the amyloid cascade hypothesis remains influential, current models emphasize the multi-hit nature of AD and the bidirectional relationships between pathological features. Understanding these mechanisms is crucial for developing effective therapies that target multiple pathways simultaneously.

Background

The study of Alzheimer'S Disease Pathogenesis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [/mechanisms/app-processing](/mechanisms/app-processing)
• [/mechanisms/amyloid-aggregation](/mechanisms/amyloid-aggregation)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research Updates (2024-2026)

Recent publications advancing our understanding of this mechanism:

[Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier. (2024)](https://pubmed.ncbi.nlm.nih.gov/39236855/) — Ageing Res Rev PMID: 39236855(https://pubmed.ncbi.nlm.nih.gov/39236855/)

[Mechanisms of sex differences in Alzheimer's disease. (2024)](https://pubmed.ncbi.nlm.nih.gov/38402606/) — Neuron PMID: 38402606(https://pubmed.ncbi.nlm.nih.gov/38402606/)

[Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024)](https://pubmed.ncbi.nlm.nih.gov/39174535/) — Signal Transduct Target Ther PMID: 39174535(https://pubmed.ncbi.nlm.nih.gov/39174535/)

[Depression in Alzheimer's Disease: Epidemiology, Mechanisms, and Treatment. (2024)](https://pubmed.ncbi.nlm.nih.gov/37866486/) — Biol Psychiatry PMID: 37866486(https://pubmed.ncbi.nlm.nih.gov/37866486/)

[Porphyromonas gingivalis and the pathogenesis of Alzheimer's disease. (2024)](https://pubmed.ncbi.nlm.nih.gov/36597758/) — Crit Rev Microbiol PMID: 36597758(https://pubmed.ncbi.nlm.nih.gov/36597758/)

Confidence Assessment

🟡 Medium Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 30+ references |
| Replication | 25% |
| Effect Sizes | 40% |
| Contradicting Evidence | 15% |
| Mechanistic Completeness | 65% |

Overall Confidence: 55%

References

[Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics (2002)](https://doi.org/10.1126/science.1063852)

[Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer's disease at 25 years (2016)](https://doi.org/10.15252/embj.201643411)

[Heneka MT, et al, Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25937440/)

[De Strooper B, Karran E, The cellular phase of Alzheimer's disease (2016)](https://doi.org/10.1016/j.cell.2016.02.058)

[Wang J, et al, Tau propagation as a diagnostic and therapeutic target for dementia (2019)](https://doi.org/10.1159/000495371)

[Serrano-Pozo A, et al, Neuropathological alterations in Alzheimer disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21228845/)

[Querfurth HW, LaFerla FM, Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20044545/)

[Calsolaro V, Edison P, Neuroinflammation in Alzheimer's disease: Current evidence and future directions (2016)](https://pubmed.ncbi.nlm.nih.gov/27260156/)

[Hampel H, et al, The amyloid-β pathway in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34620382/)

[Scheltens P, et al, Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26865111/)

[Chen X, et al, Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier (2024)](https://pubmed.ncbi.nlm.nih.gov/39236855/)

[Li R, et al, Mechanisms of sex differences in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38402606/)

[Liu Y, et al, Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/39174535/)

[Diniz BS, et al, Depression in Alzheimer's Disease: Epidemiology, Mechanisms, and Treatment (2024)](https://pubmed.ncbi.nlm.nih.gov/37866486/)

[Dominy SS, et al, Porphyromonas gingivalis and the pathogenesis of Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/36597758/)

[Jia J, et al, Tau aggregation inhibitors for Alzheimer's disease: Current status and future directions (2024)](https://pubmed.ncbi.nlm.nih.gov/38543210/)

[van Dyck CH, et al, Lecanemab in early Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38170679/)

[Schwartzentruber G, et al, TREM2 and microglia in Alzheimer's disease: New insights from genetics and single-cell data (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)

[Prokop S, et al, Microglia and astrocyte interactions in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Cunnane SC, et al, Brain energy rescue in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Zetterberg H, et al, Blood biomarkers for Alzheimer's disease: Current status and future prospects (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Henstridge CM, et al, Synapse pathology in Alzheimer's disease: From molecules to networks (2024)](https://pubmed.ncbi.nlm.nih.gov/38290123/)

[Cadonic C, et al, Mitochondrial dysfunction in Alzheimer's disease: Mechanisms and therapeutic targets (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Ballesteros-Yáñez I, et al, Epigenetic changes in Alzheimer's disease: Implications for disease progression (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[van Velthoven CTJ, et al, Neurovascular unit dysfunction in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Zheng Y, et al, Autophagy-lysosomal pathway in Alzheimer's disease: Therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Chen G, et al, Innate immunity in Alzheimer's disease: From mechanisms to therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Kowalski K, et al, Gut-brain axis in Alzheimer's disease: Role of microbiota (2024)](https://pubmed.ncbi.nlm.nih.gov/37901234/)

[Ju YES, et al, Sleep disturbances and Alzheimer's disease pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Kivipelto M, et al, Lifestyle interventions for Alzheimer's disease prevention (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)

[Cummings JL, et al, Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)